SCHEMBL269734

SCHEMBL269734

COc1cc(OC)cc(C(=O)Nc2ccc(Br)cc2C(=O)NN=Cc2ccc(C)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
POLB P06746 2/20 0.52
MAPT P10636 7/20 0.50
HPGD P15428 5/20 0.50
KDM4E B2RXH2 5/20 0.50
NPC1 O15118 4/20 0.50
ALDH1A1 P00352 3/20 0.50
RAB9A P51151 3/20 0.50
PKM P14618 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALOX12 P18054 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
LMNA P02545 5/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
GAA P10253 1/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL269733 1.00 KMT2A (0.52) KMT2AMEN1POLBMAPTHPGD
SCHEMBL267131 0.91 MAPT (0.49) KMT2AMEN1POLBMAPTHPGD
SCHEMBL267177 0.91 MAPT (0.55) KMT2AMEN1POLBMAPTHPGD
SCHEMBL267130 0.91 MAPT (0.49) KMT2AMEN1POLBMAPTHPGD
SCHEMBL267176 0.91 MAPT (0.55) KMT2AMEN1POLBMAPTHPGD
SCHEMBL268977 0.89 RAB9A (0.58) KMT2AMEN1POLBMAPTHPGD
SCHEMBL268976 0.89 RAB9A (0.58) KMT2AMEN1POLBMAPTHPGD
SCHEMBL265854 0.88 RAB9A (0.55) KMT2AMEN1POLBMAPTHPGD
SCHEMBL265855 0.88 RAB9A (0.55) KMT2AMEN1POLBMAPTHPGD
SCHEMBL267003 0.88 MAPT (0.56) KMT2AMEN1POLBMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KMT2A 4564/4885MEN1 1194/4885POLB 3843/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KMT2A 4603/4885MEN1 1638/4885POLB 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.